Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto
AssigneesCymaBay Therapeutics, Inc., DiaTex, Inc.
InventorsEdward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
Life of this patent
Estimating the term…
Abstract
The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
Claims20
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8° 2θ and an infrared spectrum comprising at least one peak selected from at about 3322 cm−1 and at about 2886 cm−1.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8° 2θ and a Raman spectrum comprising at least one peak selected from at about 3087 cm−1 and at about 1663 cm−1.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8° 2θ, an infrared spectrum comprising at least one peak selected from at about 3322 cm−1 and at about 2886 cm−1, and a Raman spectrum comprising at least one peak selected from at about 3087 cm−1 and at about 1663 cm−1.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8° 2θ, about 22.0° 2θ, and about 29.3° 2θ;
- and an infrared spectrum comprising peaks at about 3322 cm−1 and about 2886 cm−1.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8° 2θ, about 22.0° 2θ, and about 29.3° 2θ;
- and a Raman spectrum comprising peaks at about 3087 cm−1 and about 1663 cm−1.
Dependencies are inferred from the claim text.